A Phase 3 interventional study of Telmisartan + Amlodipine + Rosuvastatin and Telmisartan + Amlodipine in Hypertension and Dyslipidemia, sponsored by Daewon Pharmaceutical Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 79 Years. Per ClinicalTrials.gov, last updated 2018-02-01.
Sponsored by Daewon Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.
Among the 99 studies testing telmisartan in Hypertension, this one is the 59th largest by enrollment, is one of 2 that started in 2016, is one of 40 in phase 3, and was the 77th registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:
Chong Kun Dang Pharmaceutical · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 19 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 5 · Phase 3 40 · Phase 4 32
First in 1997; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 129 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 184 across the 99 interventional studies. Of the 91 that completed or were terminated, 14 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 99 have an industry lead sponsor. The 10 most frequent:
Daewon Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 7 are open to participants now.
Daewon Pharmaceutical Co., Ltd. has 2 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 99 studies testing telmisartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Multicenter, Randomized, Double-blinded, Double-dummy, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Treatment with DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients with Hypertension and Dyslipidemia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
qd PO, Twynsta(telmisartan/amlodipine) + Crestor(rosuvastatin)
Drug: Telmisartan + Amlodipine + Rosuvastatin
qd PO, Micardis(telmisartan) + Crestor(rosuvastatin)
Drug: Telmisartan + Rosuvastatin
qd PO,Twynsta(telmisartan/amlodipine)
Drug: Telmisartan + Amlodipine
Drug pages: Telmisartan · Amlodipine · Rosuvastatin
Telmisartan + Amlodipine + Rosuvastatin + Telmisartan placebo
Drug pages: Telmisartan · Amlodipine
Telmisartan + Amlodipine + Rosuvastatin placebo + Telmisartan placebo
Drug pages: Telmisartan · Rosuvastatin
Telmisartan + Amlodipine placebo + Rosuvastatin + Telmisartan placebo
Change of MSSBP(Mean Sit Systolic Blood Pressure) from baseline
Time frame: 8-week
Change of LDL-C(Low Density Lipid Cholesterol) from baseline
Time frame: 8-week
Ran from Oct 2016 to primary completion in Sep 2017, 11 months.
Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 11 months is below that.
Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Telmisartan · Amlodipine · Rosuvastatin
Daewon Pharmaceutical Co., Ltd. →